Trade

with

DexCom Inc
(NASDAQ: DXCM)
AdChoices
42.84
-1.24
-2.81%
After Hours :
42.84
0.00
0.00%

Open

44.58

Previous Close

44.08

Volume (Avg)

662.06k (638.50k)

Day's Range

42.12-44.58

52Wk Range

27.10-49.83

Market Cap.

3.33B

Dividend Rate ( Yield )

-

Beta

0.46

Shares Outstanding

75.48M

P/E Ratio (EPS)

-

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
-28.90M
Operating Margin
-18.06
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

96.77%

Top 10 Institutions

46.73%

Mutual Fund Ownership

60.72%

Float

97.59%

5% / Insider Ownership

2.95%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Federated Kaufmann Fund

  •  

    3,389,253

  • 1.17

  • 4.50

  • T. Rowe Price New Horizons Fund

  •  

    2,594,000

  • 36.16

  • 3.44

  • Fidelity® Contrafund® Fund

  •  

    1,968,663

  • 4.22

  • 2.61

  • Artisan Small Cap Fund

  •  

    1,499,334

  • -5.56

  • 1.99

  • Baron Small Cap Fund

  •  

    1,250,000

  • 0.00

  • 1.66

  • Vanguard Small Cap Index

  •  

    1,245,421

  • 0.41

  • 1.65

  • iShares Russell 2000 (AU)

  •  

    1,161,576

  • -1.02

  • 1.62

  • Vanguard Total Stock Mkt Idx

  •  

    1,159,170

  • 0.37

  • 1.54

  • Vanguard Small Cap Growth Index Fund

  •  

    841,745

  • -1.52

  • 1.12

  • Franklin Small Cap Growth Fund

  •  

    718,900

  • 9.67

  • 0.95

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Wellington Management Company, LLP

  •  

    5,334,604

  • +46.68%

  • 7.08

  • Federated Global Inv Mgmt Corp

  •  

    4,446,933

  • +888.21%

  • 5.90

  • Vanguard Group, Inc.

  •  

    4,346,111

  • -1.49%

  • 5.76

  • Fidelity Management and Research Company

  •  

    4,164,634

  • -0.93%

  • 5.52

  • T. Rowe Price Associates, Inc.

  •  

    3,998,300

  • +42.13%

  • 5.30

  • Gilder Gagnon Howe & CO LLC

  •  

    3,939,999

  • -0.79%

  • 5.23

  • Artisan Partners Limited Partnership

  •  

    2,809,111

  • -2.33%

  • 3.73

  • Frontier Capital Management CO Inc

  •  

    2,107,205

  • -6.28%

  • 2.79

  • Waddell & Reed Investment Management Co

  •  

    2,095,481

  • +3.63%

  • 2.78

  • Franklin Advisers, Inc.

  •  

    1,992,996

  • +71.63%

  • 2.64

Company Profile

Sector

Healthcare

Industry

Medical Instruments & Supplies

Type

Speculative Growth

Style

Small Growth

The majority of its product revenue comes from sales of its SEVEN PLUS ambulatory continuous glucose monitoring system. The Company’s SEVEN PLUS and G4 PLATINUM systems are more invasive than current self-monitored glucose testing sy...morestems, including single-point finger stick devices, and patients may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day. Moreover, patients may not perceive the benefits of continuous glucose monitoring and may be unwilling to change their current treatment regimens. As compared to the SEVEN PLUS, the G4 PLATINUM offers additional user interface and algorithm enhancements that are intended to make its glucose monitoring function more accurate especially in the hypoglycemic range. ...moreTo address the in-hospital patient population, it entered into an exclusive agreement with Edwards to develop jointly and market a specific product platform for the in-hospital glucose monitoring market, with an initial focus on the development of an intravenous sensor specifically for the critical care market. Its products also shows how fast the body’s glucose levels are changing. It is designed to help avoid highs and lows and to help keep the glucose between the lines of the target zones. Its competitors include Roche Disetronic, Roche Diagnostics, LifeScan, Inc, Johnson & Johnson, the MediSense and Abbott Laboratories, and Bayer Corporatio. Its products are medical devices subject to extensive and ongoing regulation by the FDA and regulatory bodies in other countries.lessless

Key People

Terrance H. Gregg

CEO/Director

Dr. Jonathan T. Lord,M.D.

Chairman of the Board/Director

Jess Roper

CFO/Chief Accounting Officer/Vice President

Steven R. Pacelli

Executive VP, Divisional

Kevin R. Sayer,C.P.A.

Director/President/COO

Incorporated

1999

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: